NPCE NEUROPACE INC

UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference

UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference

MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference.

The presentation will be accessible via live webcast . A webcast replay will be available for two weeks following the presentation in the  section of NeuroPace’s Investor website at .

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:

Jeremy Feffer

Managing Director

LifeSci Advisors



EN
04/03/2025

Underlying

NPCENEUROPACE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEUROPACE INC

 PRESS RELEASE
Free
NPCE NEUROPACE INC

NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results

NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results -- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 100% of KCK holdings and $20.2 million to strengthen its balance sheet to support planned operations to reach cash flow breakeven -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Na...

21h / 36m 1 EN
 PRESS RELEASE
Free
NPCE NEUROPACE INC

UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcar...

UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast . A webcast replay will be avail...

March 4, 2025 1 EN
 PRESS RELEASE
Free
NPCE NEUROPACE INC

NeuroPace to Present at the Leerink Partners Global Healthcare Confere...

NeuroPace to Present at the Leerink Partners Global Healthcare Conference MOUNTAIN VIEW, Calif. , March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, January 10, 2025, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast . A webcast replay will be available f...

March 3, 2025 1 EN
 PRESS RELEASE
Free
NPCE NEUROPACE INC

NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Sto...

NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd. MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the previously announced plan to repurchase 5,270,845 shares of the Company’s common stock from KCK Ltd. The repurchase of these shares allowed for the organized sale by KCK Ltd. of all remaining shares it held in the Company. NeuroPace funded the repurchase of these shares using a portion of t...

February 20, 2025 1 EN
 PRESS RELEASE
Free
NPCE NEUROPACE INC

NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Result...

NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2024 after market close on Tuesday, March 4, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference c...

February 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch